Access Pharmaceuticals is an emerging biotechnology company focused on the development and commercialization of products using the companies targeted delivery systems to improve clinical outcomes for patients.
Together with our subsidiaries we have proprietary patents or rights to a number of drug delivery platforms:
The company’s primary development focus is in the area of oncology with its polymer therapeutics program. The company’s lead product, AP5346, is in Phase II clinical development and is a polymer of DACH-platinum, the active principal of oxaliplatin (Eloxatin; sanofi aventis).
Nanotechnology-based Platforms to Deliver Essential Vitamins to Diseased Cells
Prof. Hongxia Wang
We speak with Professor Hongxia Wang from QUT about a new project that hopes to utilize graphene and other low-cost carbon materials to produce commercially viable, ultra low-cost, flexible perovskite solar cells.
Moti Segev & Vlad Shalaev
In this interview, AzoNano speaks to Professor Moti Segev and Professor Vladimir Shalaev, who made surprising discoveries about photonic time crystals that challenge existing research and theories.
Siyu Chen, Ph.D.
In this interview, we discuss a new approach to surface-enhanced Raman spectroscopy that utilizes nano-pockets to capture target molecules, ensuring a highly sensitive way to detect chemical processes.
This product profile from Merck outlines information about ultrastable fluorescent silica nanobeads.
The ClearView scintillator camera that elevates your everyday transmission electron microscopy (TEM).
Achieve high-throughput co-localized imaging and in-situ nanoindentation with Bruker’s Hysitron PI 89 Auto SEM.